Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative therapies for patients with elevated cholesterol levels. Founded in 1998, Esperion has made significant strides in the cardiovascular industry, particularly in the realm of lipid management. The company is renowned for its unique approach to treating hyperlipidaemia, with its flagship product, Nexletol (bempedoic acid), offering a novel mechanism of action that complements existing cholesterol-lowering therapies. Esperion's commitment to addressing unmet medical needs has positioned it as a leader in the market, with a growing portfolio aimed at improving patient outcomes. With a strong emphasis on research and development, Esperion continues to advance its mission of transforming the treatment landscape for cardiovascular diseases, solidifying its reputation as a key player in the biopharmaceutical sector.
DitchCarbon Score
How does Esperion Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Esperion Therapeutics, Inc.'s score of 25 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Esperion Therapeutics, Inc.'s reported carbon emissions
Esperion Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific climate commitments outlined in their reduction initiatives. As such, there are no reported figures for their carbon emissions, including Scope 1, 2, or 3 emissions. Without defined reduction targets or commitments to industry-standard climate initiatives, it is unclear how the company is addressing its carbon footprint. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and emissions reduction, but specific actions or targets from Esperion Therapeutics remain unspecified.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Esperion Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
